140 related articles for article (PubMed ID: 26832839)
1. Development of Liposomal Formulation for Delivering Anticancer Drug to Breast Cancer Stem-Cell-Like Cells and its Pharmacokinetics in an Animal Model.
Ahmad A; Mondal SK; Mukhopadhyay D; Banerjee R; Alkharfy KM
Mol Pharm; 2016 Mar; 13(3):1081-8. PubMed ID: 26832839
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the
Ahmad A; Jan BL; Raish M; Rachamalla HKR; Banerjee R; Mukhopadhyay D; Alkharfy KM
Saudi Pharm J; 2019 Jul; 27(5):637-642. PubMed ID: 31297017
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid receptor-targeted liposomal delivery system for delivering small molecule ESC8 and anti-miR-Hsp90 gene construct to combat colon cancer.
Jinka S; Rachamalla HK; Bhattacharyya T; Sridharan K; Sekhar Jaggarapu MMC; Yakati V; Banerjee R
Biomed Mater; 2021 Feb; 16(2):024105. PubMed ID: 33434900
[TBL] [Abstract][Full Text] [Related]
5. Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors.
Mondal SK; Jinka S; Pal K; Nelli S; Dutta SK; Wang E; Ahmad A; AlKharfy KM; Mukhopadhyay D; Banerjee R
Mol Pharm; 2016 Jul; 13(7):2507-23. PubMed ID: 27184196
[TBL] [Abstract][Full Text] [Related]
6. Development of a Liposomal Formulation of Acetyltanshinone IIA for Breast Cancer Therapy.
Wang Q; Luo M; Wei N; Chang A; Luo KQ
Mol Pharm; 2019 Sep; 16(9):3873-3886. PubMed ID: 31389706
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
8. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
9. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature.
Herringson TP; Altin JG
Int J Pharm; 2011 Jun; 411(1-2):206-14. PubMed ID: 21443937
[TBL] [Abstract][Full Text] [Related]
10. Disposition and tissue distribution of imatinib in a liposome formulation after intravenous bolus dose to mice.
Moo KS; Radhakrishnan S; Teoh M; Narayanan P; Bukhari NI; Segarra I
Yao Xue Xue Bao; 2010 Jul; 45(7):901-8. PubMed ID: 20931790
[TBL] [Abstract][Full Text] [Related]
11. Development of a liposome formulation for improved biodistribution and tumor accumulation of pentamidine for oncology applications.
Mérian J; De Souza R; Dou Y; Ekdawi SN; Ravenelle F; Allen C
Int J Pharm; 2015 Jul; 488(1-2):154-64. PubMed ID: 25910415
[TBL] [Abstract][Full Text] [Related]
12. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J; Emerson DL; Colagiovanni DB; Abbott E; Brown EN; Drolet DW
J Pharmacol Exp Ther; 2004 Jun; 309(3):894-902. PubMed ID: 14982966
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy for Breast Cancer Stem Cells by Liposomal Delivery of siRNA against Fibronectin EDB.
Sun Y; Kim HS; Saw PE; Jon S; Moon WK
Adv Healthc Mater; 2015 Aug; 4(11):1675-80. PubMed ID: 26097122
[TBL] [Abstract][Full Text] [Related]
15. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
[TBL] [Abstract][Full Text] [Related]
16. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
18. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
19. The Delivery of a Wnt Pathway Inhibitor Toward CSCs Requires Stable Liposome Encapsulation and Delayed Drug Release in Tumor Tissues.
Li C; Liang Y; Cao J; Zhang N; Wei X; Tu M; Xu F; Xu Y
Mol Ther; 2019 Sep; 27(9):1558-1567. PubMed ID: 31350188
[TBL] [Abstract][Full Text] [Related]
20. Liposomal Formulation of a Melphalan Lipophilic Prodrug: Studies of Acute Toxicity, Tolerability, and Antitumor Efficacy.
Tretiakova D; Svirshchevskaya E; Onishchenko N; Alekseeva A; Boldyrev I; Kamyshinsky R; Natykan A; Lokhmotov A; Arantseva D; Shobolov D; Vodovozova E
Curr Drug Deliv; 2020; 17(4):312-323. PubMed ID: 32056524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
